HomeStructural heart diseaseValvular Aortic Valve

Valvular Aortic Valve

View Category
Structural heart disease

Infective Endocarditis in TAVR: What’s the Best Treatment?

Infective Endocarditis (IE) rate after TAVR ranges from 0.7% to 3.4%, depending on the different analyses, and...
solaci -
Learn More
Pulmonary Valve

Melody: One of the Pioneers in Transcatheter Pulmonary Valve Replacement with Long Term Outcomes

At 10 years of the Melody Investigational Device Exemption we can observe this device for transcatheter pulmonary...
solaci -
Learn More
Structural heart disease

HYDRA CE | New Models for TAVR Development

The Hydra CE has shown favorable one year efficacy for the new transcatheter aortic valve model, with...
solaci -
Learn More
Valvular Aortic Valve

Minimizing One of Our Major Procedures to a Minimum

In some cases, full atrioventricular (AV) block occurs beyond two days after transcatheter aortic valve replacement (TAVR)....
solaci -
Learn More
Other

The FDA Approves Sapien 3 with Alterra in Pulmonary Position

The US Food and Drug Administration (FDA) has cleared the SAPIEN 3 valve with the Alterra adaptive pre-stent...
solaci -
Learn More
Institutional News

The Most Relevant of 2021 In Structural Heart Disease

This last year, new data in structural heart disease gave way to changes in practices and new...
solaci -
Learn More
Antithrombotic Anticoagulants

PRAGUE-17: Appendage Closure vs. Direct Anticoagulant Agents

After four years of follow-up, the PRAGUE-17 study showed that appendage closure is non-inferior to direct anticoagulant...
solaci -
Learn More
Structural heart disease

CHOICE-CLOSURE | Which Closure Device for TAVR is Better?

In patients who undergo transcatheter aortic valve replacement (TAVR) through transfemoral access, a closure device based on...
solaci -
Learn More